Barrett's Esophagus Clinical Trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 349 clinical trials
Technology for Detection of SARS-Cov-2 in HIV-Positive Cancer Patients

  This study is also looking at who might be most at risk for serious complications and/or death from COVID-19.  For example, it may be that people who already have other illnesses such as HIV (Human Immunodeficiency Virus), cancer, or other infections may be more likely to get very sick if …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation

In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of paroxysmal or persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will randomize in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, preferably administered …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular Reactivity

Each participant, from both cohorts, will undergo 2 MRIs and 2 blood draws, per visit. All participants will be compensated for time taken to participate in the study. Key eligibility criteria include men and women, ages 18-35 with a BMI of 18.5-30.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

Each participant will receive active vaccine/placebo at weeks 0, 4, 12, and 24 delivered by electroporation after intramuscular injection. The primary efficacy outcome will be based on HIV-specific immunologic assays at baseline and week 26.

  • 0 views
  • 19 Feb, 2024
  • 1 location
MRI Assessment of Hip Fracture Risk and Therapy Response in HIV/HCV Coinfection

HIV+/HCV+ coinfection is predicted to decrease bone strength, present abnormal trabecular structure, increase cortical porosity, and present abnormal marrow fat fraction, in comparison to the HCV+ and uninfected cohorts. Group differences are predicted to be less pronounced in BMD as assessed by DXA and FRAX scores. Identical parameters will be …

  • 0 views
  • 19 Feb, 2024
  • 1 location
SPYAL HTN-ON Med for Hypertension

The kidneys play an important role· in blood pressure control and it is believed that certain nerves in the kidney are overactive in patients with hypertension and contribute to high blood pressure. Medications alone may not be enough to control your blood pressure. Previous research has shown that disrupting the …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Epidemiological study to characterize the prevalence and distribution of lipoprotein (a) levels among patients with established cardiovascular disease.

Similar to other blood lipids, such as the "bad cholesterol", lipoprotein (a) levels were found to be associated with the risk of hardening of the arteries, known as atherosclerosis, which leads to conditions such as heart attacks, stroke, or peripheral artery disease (severe pain in legs while walking or lower …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors

If any subjects clear HCV spontaneously within the first four weeks post-transplantation, and do not require treatment, subjects will be added until there have been 10 HCV-negative subjects who receive a heart transplant from an HCV-positive donor, develop HCV, and are then treated for their HCV with Zepatier.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Strategic Management to Optimize Response to Cardiac Resynchronization Therapy

WIRB will be the Main IRB and Penn will be the relying IRB. NYHA Class I-II patients are now eligible for CRT following the MADIT CRT study, and there are no prior data for these patients using the SmartDelay feature.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Daily Liraglutide for Nicotine Dependence

Individuals who are eligible and decide to participate will receive the study medication (or placebo) and 8 sessions of smoking cessation counseling at no cost. Study participants will be compensated for time and travel. Participation in this study is completely voluntary and any information we collect about you will be …

  • 0 views
  • 19 Feb, 2024
  • 1 location